Comparing Anavex Life Sciences (NASDAQ:AVXL) & Surrozen (NASDAQ:SRZN)

Anavex Life Sciences (NASDAQ:AVXL) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Insider & Institutional Ownership

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 43.5% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Anavex Life Sciences and Surrozen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-37.50%	-34.08%
Surrozen	N/A	-120.51%	-54.68%

Valuation and Earnings

This table compares Anavex Life Sciences and Surrozen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$43.00 million	($0.55)	-14.27
Surrozen	$10.00 million	3.85	-$43.04 million	N/A	N/A

Anavex Life Sciences has higher earnings, but lower revenue than Surrozen.

Risk & Volatility

Anavex Life Sciences has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Anavex Life Sciences and Surrozen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	0	0	2	1	3.33
Surrozen	0	0	2	0	3.00

Anavex Life Sciences presently has a consensus price target of $44.00, indicating a potential upside of 460.51%. Surrozen has a consensus price target of $38.50, indicating a potential upside of 225.17%. Given Anavex Life Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Surrozen.

Summary

Anavex Life Sciences beats Surrozen on 6 of the 10 factors compared between the two stocks.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.